COVID-19 Information Center

COVID-19 INFORMATION CENTER

Updated: July 28, 2020

We recognize that this may be a challenging and stressful time, especially if you are a patient managing a serious illness. As the COVID-19 global pandemic continues to evolve, we are committed to doing everything we can to deliver for patients, to keep our staff and their families safe, and to help the communities where we live and work reduce the number of people exposed to the virus.

Amgen’s COVID-19 Priorities
- Ensuring the safety and well-being of our 23,000+ Amgen employees around the world
- Continuing to serve patients – those currently on Amgen medicines and those that stand to benefit from potential new medicines in our pipeline
- Contributing our therapeutic antibody and immunology expertise to the fight against COVID-19
- Lending a helping hand in the communities where we live and work

Latest Updates

September 17, 2020

Lilly and Amgen Announce Manufacturing Collaboration for COVID-19 Antibody Therapy

September 1, 2020

Large deCODE Study Tests Durability of Antibody Response to SARS-CoV-2 Infection

August 3, 2020

Members of the COVID R&D Alliance and Quantum Leap Healthcare Collaborative Enroll First Patients in I-SPY COVID Trial

Leveraging Our Science

Supporting Our Staff

Serving Our Communities

Frequently Asked Questions

Patients

Where should I go if I have a COVID-19 question about an Amgen medicine I’m taking?
- If you have questions about your Amgen medication, you can reach us via phone in the U.S. at 1-800-772-6436. If you live outside of the U.S., local contact information by country can be found here. If you have any questions about your treatment plan because of concerns about COVID-19, it is important to consult with your doctor.

Where can I find Amgen's product websites?
- For general information specific to a product, please visit the product websites here.

Where can I find more information if I'm in an Amgen Clinical Trial?
- With the situation around COVID-19 being so fluid and dynamic, we respectfully request that you contact your Clinical Site Investigator (Medical Doctor) for guidance with respect to the site’s current availability to receive your visit, study procedures, treatment (if applicable) or any safety issues.
- Amgen continues to expect data read-outs from the fully enrolled potentially pivotal AMG 510 (sotorasib) Phase 2 non-small cell lung cancer study, the tezepelumab Phase 3 asthma study in collaboration with AstraZeneca, and the omecamtiv mecarbil Phase 3 heart failure study in collaboration with Cytokinetics in Q4 2020. (Updated: July 28, 2020)
- Study procedures are being implemented consistent with recent guidance from regulators to maintain patient safety and study data integrity.
- Enrollment in our clinical studies has rebounded in recent weeks, and we have resumed enrollment to most of the studies that we paused due to COVID-19. We are also putting in place strategies to mitigate the uncertainties in clinical research created by any potential regional outbreaks of COVID-19. (Updated: July 28, 2020)
- Medical conferences and journals are being engaged to ensure continued dissemination of important data in a timely manner.

What can I do if alcohol wipes are unavailable that are required for injection?
- During the COVID-19 pandemic, cleaning with soap and water may be an alternative. Our Instructions for Use (IFU) provides guidance that alcohol wipes are preferred. However, if you are out of alcohol wipes, please consult with your healthcare provider.

Can I receive my medication without going to a pharmacy?
- Many pharmacies are now offering mail order, some even do it free of charge. Please call your pharmacy to see what options are available to you.
- Our teams are working to address continuity of care issues and exploring novel solutions such as alternate sites of care, mobile nurse administered injections and prescription fills at specialty and retail pharmacies. We are also working with policy makers and advocacy organizations to address treatment challenges in this environment.

What do I do if I am on an Amgen medicine and recently lost my health insurance?
- The Amgen Safety Net Foundation (ASNF) may be able to help. To support U.S. patients who may be newly uninsured due to a COVID-19 related job loss, ASNF is providing temporary enrollment to those who meet eligibility requirements.
- You can learn more about this temporary enrollment visit www.amgensafetynetfoundation.com/covid-19.html or by calling 1-888-762-6436.
- ASNF is a nonprofit patient assistance program established in 2001, sponsored by Amgen. ASNF was designed to assist patients who have a financial need and are uninsured or the insurance plan excludes the Amgen medicine. ASNF supports qualifying residents of the U.S. and its territories.

Supply

Is there any interruption to the supply of medicines based on COVID-19?
- We continued to have success in supplying “every patient, every time” with our medicines. (Updated: July 28, 2020)

Research and Development

What is Amgen doing about COVID-19 from an R&D standpoint?
- Amgen is working collaboratively with other biotechnology companies, academic institutions, the Administration and other government research entities to identify effective treatments for COVID-19 as quickly as possible:

Medical Professionals

Where do I go to report an adverse event or contact a medical information professional?
- For product questions, to report an adverse event or safety-related issue, or to report a quality issue with a product or device, call +1 800-772-6436 (800-77-AMGEN) or +1 805-447-3505. Local contact information by country can be found here.
- U.S. healthcare professionals can also visit www.amgenmedinfo.com.

My patient recently lost their job and insurance due to COVID-19. Where can I direct them?
- The Amgen Safety Net Foundation (ASNF) may be able to help. To support U.S. patients who may be newly uninsured due to a COVID-19 related job loss, ASNF is providing temporary enrollment to those who meet eligibility requirements.
- Your patient can visit www.amgensafetynetfoundation.com/covid-19.html or by calling 1-888-762-6436.

Employees and Community

What is Amgen doing to limit the spread of COVID-19 on its campuses?
- Since March 16, all employees who were able to work from home have been doing so. This includes staff at our corporate headquarters in Thousand Oaks, CA.
- Our field staff in the U.S. have moved to an approach that ensures continuity of support through a blend of virtual and in-person engagements. This approach allows us to have safe interactions while adapting to the dynamic situation of COVID-19.
- Amgen has suspended international business travel and limited domestic travel in the U.S., including attendance at medical congresses, conferences and other large events.
- Enhanced cleaning procedures and visitor screenings were implemented at all Amgen locations since the beginning of the pandemic, and we are taking measures at our sites to ensure physical distancing. We will also conduct temperature screenings and COVID-19 testing, where permitted under local requirements.

How is Amgen returning employees to the workplace and field and what safety measures are you following to maintain the safety of the workplace?
From the beginning, our top priority has been ensuring the health and safety of our people. Close to 20% of employees have been working onsite across the globe and we’ve learned from that, giving us confidence we can keep additional people healthy and safe as they return. We will return more staff to the workplace and field when it’s safe to do so. The timing and pace will be different for every location based on local conditions. We are taking the following measures to maintain the safety of our workplaces:
- Occupancy limits to allow for physical distancing
- Continued business travel and external meeting attendance restrictions
- Personal protective equipment
- Temperature screening
- COVID-19 testing and contact tracing
- Daily enhanced cleaning of high-touch areas
- Employees instructed to clean workstations before and after use
- Behavior reminders… stay home when unwell or when caring for someone who is unwell, wash hands frequently

What types of support and assistance is Amgen providing for its employees?
Financial Support
- We have committed to pay continuity for employees and will assess the duration of that commitment as the situation evolves.
- We are providing staff working from home in the U.S. and Puerto Rico a monthly stipend for home broadband Internet access along with an allowance to purchase any necessary home office equipment.
Working from Home Assistance
- We have set up an internal website dedicated to COVID-19 for employees to review updates, video messages from leadership, podcasts, access to training, and frequently asked questions.
- We have launched an additional teleconferencing platform globally with dedicated technical support.
- Ongoing online training and development is being used by thousands of employees.
Employee Wellness Resources
- We have launched a virtual health and wellness program for all Amgen team members with an emphasis on work-at-home strategies.
- We have implemented a virtual workout, nutrition, and yoga app offering for all of our Amgen team members around the world with hundreds of regionally appropriate online programs free of charge.
- We are offering mental health resources, including virtual coaching, therapy sessions, meditation and mindfulness programs.
- We are providing manager resources, such as resilience training, to help our leaders assist their teams through this period of dynamic change.
- Our largest medical plan is offering telemedicine visits for all illnesses with no deductibles or co-insurance for 90 days to encourage the safety of our team members, their families and healthcare providers.

Is Amgen or the Amgen Foundation doing anything in the community in response to COVID-19?
- Amgen and the Amgen Foundation have made an initial commitment of up to $12.5 million in COVID-19 relief funds to support emergency response efforts in Amgen’s U.S. and international communities, patient-focused organizations that are mounting their own response efforts, and international relief efforts by Direct Relief and International Medical Corps. The Amgen Foundation is also matching donations made by our employees worldwide who wish to contribute their own funds to the relief efforts. Read more here.
  
  These funds are being deployed as quickly as possible and include:
- Amgen has also expanded their Staff Volunteer program to allow medically trained staff the opportunity to take voluntary leaves to support COVID-related work in their communities.
- Additionally, the Amgen Foundation is a proud sponsor of two on-line learning platforms – Khan Academy and LabXchange – that are providing free world-class educational content to millions of students around the world at a time when many are no longer going to school.

General Information

Where should I go to find general information about COVID-19?
- Please see COVID-19 guidance from the World Health Organization or the U.S. Centers for Disease Control and Prevention.

Resources

U.S. Centers for Disease Control and Prevention
World Health Organization

Patients and Medical Professionals

For product questions, to report an adverse event or safety-related issue, or to report a quality issue with a product or device, call +1 800-772-6436 (800-77-AMGEN) or +1 805-447-3505.

Local contact information by country can be found here.

U.S. healthcare professionals can also visit www.amgenmedinfo.com.

Products

For general information specific to a product, please visit the product websites here.

Suppliers

Please see our Supplier Contact Information page.

Media

If you are member of the media and have an inquiry, reach us here.

Donation Requests

We are pleased to announce that our initial commitment of funds to support U.S. and global relief efforts to address critical needs in communities impacted by the COVID-19 pandemic has been fully allocated. You can view information about Amgen’s COVID-19 response and $12.5 million relief contribution here. If you have a funding request, please submit your inquiry to the appropriate funding category listed on our Grants and Giving page.